MedPath

A comparative study between 2% Sertaconazole vs topical 1% Butenafine in tinea infections of skin

Not Applicable
Completed
Conditions
Tinea infections of skin
Registration Number
CTRI/2012/06/002714
Lead Sponsor
Department of Pharmacology and Department of Skin and VD CU Shah Medical College and Hospital
Brief Summary

This is " A randomized open label controlled comparative trial to evaluate the efficacy, safety and cost effectiveness between 2% Sertaconazole vs 1% butenafine in tinea infections of skin." This study was conducted at C.U. Shah Medical College, Dudhrej road, Surendranagar as a part of P.G. Thesis.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
125
Inclusion Criteria

New cases of tinea infections of skin from skin OPD.

Exclusion Criteria
  1. Follow up cases 2) Pregnant and Lactating women 3) patients having hypersensitivity to one of the antifungal agents used in the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
a) Efficacy( 1. Change in baseline sign and symptom score 2. Change in Physicians Global Evaluation Response b). Safety (No. Of patients developing ADRs and type of ADRs) c). Cost effectivenes (Incremental cost and Incremental effectiveness)a) Efficacy( 1. Change in baseline sign and symptom score 2. Change in Physicians Global Evaluation Response b). Safety (No. Of patients developing ADRs and type of ADRs) c). Cost effectivenes (Incremental cost and Incremental effectiveness)
Secondary Outcome Measures
NameTimeMethod
1) Clinicomycological correlation2)Relapse rate asssessment

Trial Locations

Locations (1)

Department of Skin and VD and Department of Pharmacology

🇮🇳

Surendranagar, GUJARAT, India

Department of Skin and VD and Department of Pharmacology
🇮🇳Surendranagar, GUJARAT, India
Saket J Thaker
Principal investigator
09820599985
saketthaker@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.